Answers are grounded in this paper and cite their sources.
Differentiated thyroid cancer (DTC) represents the most prevalent endocrine malignancy and includes papillary, follicular, and oncocytic thyroid carcinomas. Despite generally favorable survival outcomes, disease persistence, recurrence, and radioiodine resistance remain important clinical challenges. Recent advances in molecular diag-nostics, histopathological classification, and risk-adapted treatment have substantially transformed approaches to DTC management.
No takes yet. Share an insight, caveat, or question.
Omiljonov et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: